Welcome to our dedicated page for Henry Schein news (Ticker: HSIC), a resource for investors and traders seeking the latest updates and insights on Henry Schein stock.
Henry Schein (HSIC) delivers essential healthcare products and services to dental, medical, and animal health practices worldwide. This news hub provides investors and industry professionals with timely updates on corporate developments, financial performance, and strategic initiatives.
Track all official announcements through our curated collection of press releases and verified news coverage. Stay informed about earnings reports, product launches, partnership agreements, and operational milestones that shape Henry Schein's position in global healthcare distribution.
Key updates include acquisitions expanding service capabilities, technological innovations in supply chain management, and regulatory developments affecting medical device distribution. Our repository eliminates fragmented research by consolidating critical information from multiple sources.
Bookmark this page for efficient monitoring of HSIC's market activities. Return regularly to access new filings, leadership updates, and analysis of trends impacting healthcare providers and distributors.
Henry Schein (Nasdaq: HSIC) expanded its agreement with vVARDIS to become the exclusive U.S. distributor of Curodont™ Repair Fluoride Plus across all dental market segments, effective January 1, 2026.
The expanded deal broadens prior 2024 exclusivity for Dental Service Organizations to include general dentistry, orthodontics, and pediatric dentistry nationwide. vVARDIS founders report having accessed over 10% of U.S. dental offices and treated more than 500,000 patients with Curodont. Henry Schein is currently the market leader selling Curodont to general practitioners and DSOs in the U.S. The product offers a drill- and needle-free treatment for early-stage cavities, which the companies describe as an opportunity to increase in-office care for untreated early lesions.
Henry Schein One (NASDAQ:HSIC) unveiled natively embedded AI workflows for Dentrix and Dentrix Ascend at the 2025 Greater New York Dental Meeting (Nov 30–Dec 3, 2025). Key features include Voice Notes for real-time chairside transcription and summaries, Forms that capture insurance data from a photo, Eligibility Pro for real-time benefits, and Detect AI (FDA-cleared) for x‑ray diagnostics. The company also announced Phones integration, a multilingual 24/7 assistant Claire, and plans for predictive scheduling, coding assistants, and unified analytics to improve intake, claims accuracy, and practice efficiency.
Henry Schein (Nasdaq: HSIC) will present at Piper Sandler’s Healthcare Conference on December 2, 2025 at 9:00 a.m. ET at the Lotte New York Palace Hotel in New York.
Investors can listen to the presentation via live webcast at www.henryschein.com/IRwebcasts. Replays will be posted on the Henry Schein investor website after the presentation.
VideaHealth and Henry Schein One (HSIC) launched the Impact Panel, an enhancement to Detect AI that embeds real-time AI findings and patient education directly into Dentrix and Dentrix Ascend imaging workflows on November 5, 2025.
Key features include an interactive odontogram, AI summaries showing tooth damage percentages and bone-level summaries by quadrant, on-screen diagrams, QR codes and print options. The Impact Panel is included at no additional cost for Detect AI users. Practices using the QR feature have reported a 19% increase in case acceptance.
Henry Schein One (NYSE:HSIC) announced a strategic partnership with AWS to integrate generative AI across its dental platforms, including Dentrix, Dentrix Ascend, and Dentally. The initiative targets AI-native workflows for scheduling, imaging, documentation, claims validation, pricing, and patient engagement to reduce administrative burden and improve outcomes.
The rollout will leverage AWS services such as Amazon Bedrock and Transcribe Medical and aims for global scalability across the U.S., U.K., and E.U. The companies emphasize security, regulatory compliance, and interoperability as core design principles.
Henry Schein (Nasdaq: HSIC) will present at two investor conferences in November 2025 and provide live webcasts and replays.
Presentations: Stifel Healthcare Conference at Lotte New York Palace Hotel on November 12, 2025 at 11:20 AM ET, and Jefferies Healthcare Conference at ME Hotel London on November 18, 2025 at 2:30 PM GMT / 9:30 AM ET. Webcasts and replays will be available at www.henryschein.com/IRwebcasts.
Henry Schein (Nasdaq: HSIC) will release its third quarter 2025 financial results before the market opens on Tuesday, November 4, 2025. The company will host a live webcast of its earnings conference call the same day beginning at 8:00 A.M. ET.
Speakers include Stanley M. Bergman, Chairman and CEO, and Ronald N. South, SVP and CFO. Investors can access the live call and a replay via the company investor website at https://investor.henryschein.com/webcasts.
The Aspen Group (NASDAQ:HSIC) announced a nationwide partnership with Planmeca to deploy advanced digital imaging across its Aspen Dental network of more than 1,100 locations on Oct. 15, 2025. Selected hardware includes Planmeca Viso and ProMax CBCT units plus ProX, ProSensor HD and ProX GO 2D, featuring Planmeca CALM and Ultra Low Dose protocols to reduce retakes and radiation exposure.
Henry Schein will support installation with a nationwide team of over 900 technicians, warranty options, and integration of Planmeca Romexis software and Planmeca Insights for real-time device data and operational monitoring.
Henry Schein (Nasdaq: HSIC), the leading provider of healthcare products and services to dental and medical practitioners, has announced a new $750 million share repurchase program. This initiative comes in addition to the company's existing $500 million repurchase program announced in January 2025.
The new authorization represents approximately 9.0% of outstanding shares at the current stock price, with the company having 118.6 million shares outstanding as of September 8, 2025. The purchases will be conducted through open market or negotiated transactions, demonstrating management's confidence in their 2025-2027 BOLD+1 Strategic Plan.
FAQ
What is the current stock price of Henry Schein (HSIC)?
What is the market cap of Henry Schein (HSIC)?
